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Pharmaceutical analysis provides information on the identity,  purity,  
content and stability of starting materials,  excipients and active 
pharmaceutical ingredients (APIs) 1.  It  is a discipline that in its course 
provides information and guidance on the exploitation of sophisticated 
technological instrumentation and advanced laboratory methodologies in 
the analysis of drug substances ,  with the purpose  of achieving its’  
ultimate objective to improve the quality of li fe with  better and safer 
drugs 2.   A medicinal preparation is a substance or a combination of 
substances which is  used in humans and/or animals in order to restore 
correct or modify a physiological function by exerting pharmacological,  
immunological  or a metabolic action 3.  Pharmaceutical control of 
medicinal preparations is necessary and crucial to the public health to 
ensure that these medicines meet the acceptable standards of quality,  
safety and efficacy.  The medicinal products  are available in different 
dosage forms (ointments,  tinctures,  pil ls,  lotions,  suppositories,  
infusions,  drops,  etc.) and consist of the  active pharmaceutical  substance ,  
pharmaceutical excipient(s) and,  commonly,  impurities that usually 
appear during the synthesis of the pharmaceutical  ingredient ;  they are 
usually monitored according to the guide lines of the ICH (International 
Conference on Harmonization of Technical  Requirements for Registration 
of Pharmaceuticals for Human Use) and the pharmacopoeias 11 above.  
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Pharmacopoeias are official  reference manuals published by the authority 
of the government  according to the World Health Organization directives; 
it  contains detailed monographs on the requirements and test methods 
for active ingredients and other products used for therapeutic purposes,  
and is essential  for  guidance in the production, testing or marketing of 
medicinal products.  
In drug control,  the chromatographic separation methods are among the 
most important  laboratory techniques used to achieve its’  course 
objective.  High Performance Liquid Chromatography (HPLC) is  the most 
used analytical  technique in drug analysis,  environmental analysis and 
food products analysis.  It  provides both quantitative and qualitative data 
in one run 4.   Although it  is one of the m ost sophisticated technologies in 
the field of analysis,  the increasing efforts nowadays for the evaluation of 
trace impurities to improve the safety and quality of pharmaceuticals and 
food products,  has further encourage technology expert to design a better 
LC-system that would increase the separation performance,  decrease the 
analysis time and generate a higher procedure effici ency5.  Nowadays,  
chromatographic methods among other application are  massively 
employed in pharmaceutical industry,  especially in the quality control 
(QC) and quality assurance (QA) monitoring processes; they are integral 
tools to ensure the compliance of the manufacturers with the current 
Good Manufacturing Practice and Go od Laboratory Practice.  
9 
 
Quetiapine fumarate is novel  atypical antipsychotic used to treat 
symptoms of psychiatric disorders such as schizophrenia and bipolar 
disorders.  It  is  among the newest antipsychotic drugs,  which in the 
recent conducted clinical  trials has shown improved tolerance of the drug 
for longer treatments and fewer neurological  side effec ts compared to the 
older agents 6. In this thesis,  the determination of the active ingredient of 
the novel antipsychotic drug and other related substances was carried 
out using Ultra-Fast Liquid Chromatography as a method with higher 
sensitivity of trace impurities,  shorter analysis time and overall higher 
















The aim of this  work is to convert conventional HPLC analytical  method 
to the conditions of Ultra-Fast Liquid Chromatography. The analytical 
method is adopted to determine Quetiapine related substances in the 
preparation.  New method should need less organic solvents,  should s ave 
time, it  should be validated with satisfactory parameters to use it  for 














3 THEORETICAL PART 
 
3.1 QUETIAPINE FUMARATE  
Quetiapine fumarate  is a  second-generation antipsychotic medication  
launched in the market by the laboratories of AstraZeneca 
pharmaceutical company under the brand name Seroquel™.  It  is indicated 
for the treatment of schizophrenia and acute manic episodes of bipolar 
disorders 7.  Quetiapine was approved by the US Food and D rug 
Administration in 1997.  
 
3.1.1  THE CHEMISTRY OF QUETIAPINE FUMARATE  
Quetiapine fumarate ,  2-(2-(4-dibenzo [b,f][1,4]thiazepine -11-yl-1-
piperazinyl)ethoxy)ethanol fumarate (Fig.  1 ) belongs to a new chemical 





Figure 3.1 The chemical structure of quetiapine fumarate 
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3.1.2 THE PHARMACOLOGY OF QUETIAPINE FUMARATE 
3.1.2.1 MECHANISM OF ACTION AND INDICATIONS 
 Quetiapine fumarate is believed to mediate it  effect by acting at multiple 
neurotransmitter receptors in the brain.  It  antagonizes the dopamine and 
serotonin receptors,  specifically Dopamine D(1) and D(2),  serotonin 5 -
HT(1A) and 5-HT(2),  histamine H(1),  adrenergic  alpha(1) and alpha(2) 
receptors.  The efficacy in the treatment of the symptoms of 
schizophrenia;  bipolar depression and bipolar mania is  supposed to be 
due to a combination of D(2) and 5 -HT(2) receptors 1011.   
In contrast to the older antips ychotic agents,  quetiapine has a better 
therapeutic profi le in that it  is less associated with the common  adverse 
effects witnessed in most of the antipsychotic medications.   The drug has 
minimal activity on dopamine receptors in the nigrostriatal  dopamine 
system, the part of the brain responsible for the extrapyramidal side 
Figure 3.2 Quetiapine synthesis 
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effects; and also has minimal effects on the  tuberoinfundibular dopamine 
system, thereby avoiding the problem of hyperprolactinemia, frequently 
associated with antipsychotic therapy . Patients on long-term treatment 
with quetiapine have reported high compliance,  increased ability to 
function and improvement on the symptoms accompanying the disorder ,  
therefore its use is particularly appropriate in patients sensitive to side 
effects (e.g.  childre n and elderly patients) 6.    
In the off-label use of atypical antipsychotics,  quetiapine has shown to be 
beneficial  in the treatment of generalized  anxiety disorder,  when 
compared to placebo in three large controlled trials 12.   
3.1.2.2 ADVERSE EFFECTS 
The histamine H(1) antagonism is believed to be responsible for the most 
common adverse effects of the medication which are dizziness and 
somnolence 13.  Other common side effects that have been reported during 
treatment with quetiapine are:  
 fatigue, dry mouth,  sore throat,  dizziness,  abdominal pain,  constipation, 
upset stomach,  orthostatic hypotension,  inflammation or swelling of the 
sinuses or pharynx, increased appetite,  and weight gain 10.   
Serious but rare side effects that have been reported in less than 1% of 
the patients  are: prolonged QT interval ,  syncope, leukopenia,  
neutropenia,  pancreatitis,  seizures,  and suicidal  thoughts.  
Rhabdomyolysis has also been considered as one of the rare but serious  
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adverse events related to quetiapine  and therefore should be monitored 
during treatment 14.  
3.1.2.3 CONTRAINDICATIONS  
Apart from the hypersensitivity to this drug and/or this class of 
chemicals,  no other specific contraindications have been determined so 
far.   
3.1.2.4 PREGNANCY AND BREAST FEEDING 
In an observational study of 54 childbearing women under antipsychotic 
treatment,  among different antipsychotics (olanzapine, haloperidol,  
risperidone) quetiapine has shown the lowest placental passage with 
24.1%, a significant differen ce compare to olanzapine 72.1% being the 
highest 15.  In one case report the use of 300 to 400 mg quetiap ine in a 
pregnant woman has shown no infant abnormalities after birth  and at six 
month of age the infant was developing normally 16.  However,  quetiapine 
is considered a category C according to the FDA’s Pregnancy Category and 
should therefore be used only if  the potential  benefits outweigh the 
potential risks.  Although the limited data on  the safety of quetiapine 
during breastfeeding show no evidence of toxic ity,  infant risk cannot be 
ruled out and therefore the infants’ quetiapine plasma levels should be 






3.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
High Performance Liquid Chromatography is a laboratory technique used 
for separating complex mixtures into individual substances .  It  is a highly 
improved form of column chromatography that has found an extensive 
use in the pharmaceutical analysis for a variety of applications,  for 
example: isolation of natural pharmaceutically active compounds; 
identifying undesirable impurities in ph armaceutical substances;  assay of 
pure drugs; and determination of the related substances p resent in 
various drug dosage forms 2.  
Its’  detection methods are highly automated and sensitive and instead of 
using gravity for the extraction of the solvent,  it  runs under high 
pressure up to 400 atmospheres which makes it much faster.   
PRINCIPLE:  A mixture of components or a drug sample is dissolved in a 
proper organic solvent and injected into a moving liquid known as the 
“the mobile phase”.  The mobile phase is  pumped through a column , a solid 
tube composed of densely packed particles called “the stationary phase”. The 
components of the drug sample are transported by the mobile phase to 
the column and brought into contact with stationary phase .  Based on the 
physical characteristics of their molecule entities,  the stationary phase 
will retard their migration at  diffe rent speeds.  The separation of the drug 
components is  a result  of differences in their movement through a two-
phase system and differences in the interaction of the components  with 
the stationary phase.   
16 
 
3.2.1 CHROMATOGRAPHIC MODES 
According to its’  physical  pri nciples the separation operates in different  
mechanism: 
 Size exclusion: separation of constituents is based on the radius of the 
molecule; 
 Ion exchange: used for the positively or negatively charge molecules 
(proteins, peptides, nucleic acids) and is based on their ability to exchange 
anions or cations;  
 Hydrophobic Interaction:  is based on the non-polar interaction between the 
molecule and the stationary phase, but in contrast to RPC (see below), with a 
much lower density of the hydrophobic interaction; 
 Affinity chromatography: is used for the biologically active compounds that 
have highly specific interaction with a specific ligand, and is therefore used 
whenever a suitable ligand is available for the compound of interest18. 
 Reverse Phase Chromatography: is based on the interaction of the non-polar 
regions of the molecule with the non-polar stationary phase. In contrast to 
the ‘normal phase’,  the polar constituents are eluted from the column with 
high organic mobile phase, while the non-polar constituents are retained on 
the hydrophobic stationary phase;  
 
Reversed phase chromatography is the most frequent separation 
mechanism used in drug analysis . It is an elution procedure in which the 
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mobile phase is significantly more polar than the stationary phase 19;  the 
more hydrophobic the compound the longer the retention time.  
        




A modern HPLC apparatus con sist  of the following essential 
compartments:  
 Solvent reservoir and degasser system, 
 Pumps and sample injection system, 
 Columns, 
 Detectors, 
 Strip-chart recorder, 
 Data handling device and microprocessor control2. 
 






3.2.3 THE STATIONARY PHASE 
The most frequently used type of t he stationary phase for reverse-phase 
liquid chromatography is composed of silica particles which are thinly 
coated with long-chain hydrophobic  alkyl groups (e.g.  C4,  C8 or C18) to 
interact with the analyte.  Particle size range from 3 to 10 µm, sometimes 
the size goes up to 50µm or more for preparative columns 20.  The main 
drawback of this type of composition is its’  limited stability of pH (2 -8).  
Polymeric based stationary phase is a  matrix that can be modifie d with 
different chemical groups. The advantage of this stationary phase is  its ’  




wide range of pH stability (1 -11),  but the l imited availability in the 
market its’  a  drawback.  
Zirconium based stationary phase is a novel type of sorbent with higher pH 
stability and a unique selectivity for particular compounds.  It  is ZrO 2 
matrix which can be modified by e.g.  polystyrene,  polybutadiene or C18.  
Other types of stationary phases: underivatized graphitized carbon; TiO 2 
based stationary phase 4.  
3.2.4 COLUMN 
The columns in HPLC are uti lized with densely packed sorbent particles 
which provide a great surface area for interaction of the particles and 
make possible of  the partitioning of the components in the mixture.  Most 
common packing material consists  of silica particles .  The columns are 
characterized by the particle size  (3 to 10µm) and the particle pore size 
ranging from 100 to 1000 angstroms  that make up for the  dimension of 
the column with an internal diameter  ranging from 2 to 5mm (typical  
4.6mm), length ranging from 10-30cm (typical 25cm) and.  Usually,  
smaller particles generate a higher pressure than the greater particles.  In 
addition, they also account for a  better efficiency in the separation. Si lica 
materials are sensitive to extremes of pH  especially when combined with 
the high temperature;  hence it  is recommended that the organic solvent 
should not exceed the pH of 7 in order to avoid damaging of the colu mn 
particles 21.  The columns are constructed of highly polished stainless 
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steel,  an inert material  capable of resisting the corrosive properties of 
organic solvents.   
 
3.2.4.1  Chromatographic parameters  
3.2.4.1.1  Retention factor (k’) 
  The retention factor for a given solute (also known as the capacity 
factor (k’)) is  a function of the mobile phase polarity 26.   The migration of 
individual solutes of the sample through the column depends on the 
equilibrium distribution of each solute between the mobile phase and the 
stationary phase. When the difference in the retention factors is  
sufficiently large,  the solutes elute from the col umn at different times 
and are separated.  The distribution of the solute between the two -phase 
systems is given by the distribution constant:  
 Kc = 
  
  
   
The retention factor shows how the amount of the substance is  
distributed between the stationary phase and the mobile phase and 
depends on the distribution constant (K c) and the volume of the 
stationary phase and the mobile phase 22:  




When the retention factor is  equal to 1,  the compound will be distributed 
equally between the stationary phase and the mobile phase.  If k’  value is  
21 
 
less than 1,  the elution is so fast  that determining an accurate retention 
time is very difficult.  When the retention factor is equal to 5,  there will 
be 5 times more of the compound in the stationary phase than in the 
mobile phase.  If k’  values are too high (greater than 20) the elution will 
take very long. Ideally,  k’ value for a given analyte is between 1 and  5.  
Each analyte in a sample will  have a different retention factor which can 
be determined from the chromatogram using the following equation:  
k’= 
     
  
  
Where t R is  the time between sample injection and an analyte peak 
reaching the detector at the e nd of the column; t M is the time taken for 
the mobile phase to be eluted from the column. Both these parameters 













3.2.4.1.2 Brand broadening (N) 
A columns’ efficiency is explained by the Theoretical Plate Model which supposes that the 
column contains a large number of separate layers. The peak broadening expresses how 
efficiently a compound is transported through the column. In order to obtain an optimal 
separation with sharp and symmetrical peaks, peak broadening should be limited. The 
wider the peak, the longer the retention time and the smaller will be the number of 
components that can be separated in a given time. Band broadening is expressed by the 
parameter N, called the number of theoretical plates. 
The plate number depends on the length of the column, that is to say that the longer the 
column the larger the number of the plates and thus the better the separation. The height 
of a single theoretical plate H (Height Equivalent to a Theoretical Plate), is a measure of the 
efficiency of a column per unit length of the column. The smaller the H value, the larger will 
be the number of plates22. 
 
 
Fig. 3.2.4.2 The Gaussian peak and parameters used to measure peak width24 
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3.2.4.1.3 Selectivity (α) 
The separation of two different analytes in the column is described by the separation factor, 
which is a measure of the selectivity of a chromatographic system. The separation factor 
has values greater or equal to 1. If α equals to 1 separation is not possible; the greater the 
separation factor the easier the separation22. 
 
 
3.2.4.1.4 Peak symmetry (As) 
Asymmetrical peaks can be a result of low quality or polluted columns. The symmetry factor 
(As) is used to indicate the peak symmetry: 
   As = 
     
  
 
When As equals 1.0 it signifies symmetry; when As > 1.0 the peak is tailing; when As < 1.0 the 
peak is fronting. 






W0.05  –  peak width in 1/20 of its height 
ƒ – the distance between the perpendicular and the rising part of the peak 
3.2.4.1.5 Resolution (Rs) 
Resolution is a measure of how well the peaks in the chromatogram are separated: 
Rs = 1.18 
       
       
 
tR2 and tR1 are the retention times of the peak 2 and peak 1; wh1 and wh2 are the peak widths 
at the half height of peak 2 and 1. 
Rs = 
           
     
 
The equation above is used when peak widths are measured at the base of peak 2 and 1. 






To improve the separation of the peaks the following equation uses the adjustable variables 









     
 
The plate number (N) can be manipulated by reducing the height equivalent to a theoretical 
plate by reducing the size of the stationary phase particles; the retention factor (k) can be 
optimized by changing the composition of the mobile phase; the separation factor (α) can 
also be manipulated but if α is close to 1, optimizing k’ and increasing N is not sufficient for 
a good separation4. 
3.2.4.1.6 Relative retention (r)  
In chromatography, the relative retention is the ratio of the adjusted retention factor of a 
substance relative to that of a standard, obtained under identical conditions25. 
r = 
      
      
                                                                         r = 
   
   
 
Fig. 3.2.4.5 Parameters needed to calculate resolution of peaks 
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3.2.4.1.7 The Signal/Noise Ratio 
To get a sharp, symmetrical peak the S/N ratio is used to separate the signal of interest from 





where H is the height of the peak and h is the height of the noise.  
 
 
3.2.5 SOLVENTS AND SAMPLE PREPARATION 
When using reversed phase chromatography the mobile phase is  a 
mixture of aqueous buffer and an organic solvent.  The organic solvent 
has to be pure and miscible with water.  Furthermore, it  should be inert 
towards the analyzed compounds. Most widely used or ganic solvents in 
RPC are acetonitrile,  methanol and tetrahydrofuran (THF).   Ethanol and 
isopropanol are also used in some cases .   
The elution of the analytes can be performed as isocratic elution or as 
gradient elution.  In the former mode the water-solvent composition does 
not change during the separation mechanism, while in the later the 
Figure 3.4 Signal-to-noise ratio 
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composition of the mobile phase can be changed during  the separation 
process.  
In order to get a good separation with accurate retention times , there are 
several techniques that can be employed in sample preparation prio r to 
the analysis.  To obtain a desirable k‘ value for a  solute,  the polarity of the 
solute should be close to t hat of the organic solvent.  One way to achieve 
this is by modifying the composition of the mobile phase,  i .e.  increasing 
the portion of the organic solvent (commonly 1:5 or 1:10) 4.   
In cases where the pH of the mobile phase interfere s with the sample,  
such as with compounds of  weak acidic or weak basic character (most of 
the pharmaceutical drugs) ,  the k ’  value can be increased using ion-paring 
chromatography. The addition of ion -pairing agents in the mobile phase 
will suppress the ana lytes’  ionization.  They form ionic interaction with 
the analyte and are extracted into the organic solvent as an 
electroneutral ion-pair.  In this way they modify the analytes’ 
hydrophobicity and consequently their retention factors 26.  Commonly 
used ion-pairing agents are:  
 Inorganic: Cl¯, Br¯, ClO4¯ 
 Organic: alkylammonium ions (for extraction of acids):  tetrabutylammonium-
iodide, cetyltrimetylammonium-bromide; alkylsulfonates (for extraction of bases): 
salts of pentasulfonic, hexasulfonic, heptasulfonic acids.  
 Desalting effect is  another laboratory technique used to increase the k‘ 
when preparing the sample for reversed phase chromatography.   Adding 
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inorganic salt  in the mobile phase will decrease the availability of  the 
aqueous phase and thus resulting in the extraction of the solute in the 
organic phase.  Salting-out agents are: buffers (5-0.01 mol/L),  inert 
neutral  salts e.g.  NaCl,  Na 2SO4 etc
4.   
3.2.6 PUMPING SYSTEM 
The pumps run under high pressure up to 40 MPa (400 atmospheres) and 
are responsible for delivering the mobile phase from the solvent 
reservoir to the column at constant flow rates  with minimal fluctuation. 
The modern HPLC apparatus consists of one or two pumps that can be 
programmed to vary the mobile phase components,  as is required for the 
gradient chromatography.  
3.2.7 DETECTOR 
LC-detectors are important accessories of the HPLC instrument.  When the 
analytes are eluted from the column,  they reach the detector which in 
turn converts electrical  signals of the analytes  into visual responses.  The 
visual data are collected by a data acquisition system and are depicted in 
the chromatogram as peak areas or peak heigh ts.  Their operation is very 
important and largely applied in quantitative analysis.  
The most frequently used detectors in liquid chromatography are the UV -
VIS detector,  the Fluorescence detector and the e lectrochemical detector.  
Other less frequently used but important detectors are: mass 




3.2.7.1  The Ultraviolet-visible detector  
UV detectors are used in 75-80% of HPLC analysis.  Its’  universal  
application is based on its  simple working principle; it  analyzes 
substances based on their absorption of the UV light.  These substances 
are required to contain a chromophore, i .e.  containing at least one double 
bond or unshared electrons,  which is the case with most compounds. The 
UV wavelength range is from 180 to 340nm and 400 to 700nm for the 
colored compounds that absorb in the visible region. A UV-VIS detector 
consists of a  lamp (deuterium lamp for UV spectra and/or the tungsten 
lamp for the visible spectra)  which is the source of the radiation;  the 
monochromator that narrows the emission of the radiation  and ensures 
that the UV radiation of the correct wavelength is directed through the 
flow cell ; the flow cell  (detector cell)  through which the eluent passes is  
designed in a Z-shape with dimensions of 10 mm length  and 8µL volume 
capacity; a  light-sensor (photodiode array) that converts the photons 
into current or voltage; an amplifier that modifies the output coming 
from the flow cell ; and a data acquisition system that records the signal 27.  
The UV rays emitted by t he lamp pass through the sample in the detector 
flow cell  and fall onto the photodiode array producing electrons whose 
current is recorder.  The absorbance of the UV radiation is proportional 
with the concentration of the sample passing through the cell .  Th is 
relationship is given by the Lambert’s  Beer Law:  
A= ɛ  l  c  
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ɛ  -  the molar absorptivity ,  an intrinsic property of the compound  which 
measures how much light will be absorbed by 1cm in a 1M solution of the 
sample; l  is  the length of the flow cell and c acc ounts for the 
concentration of the sample.  
 
 
3.2.7.2  Mass spectrometry  
Nowadays, mass spectrometers are common instruments in biochemical, pharmaceutical 
and analytical laboratories. The increasing demands for MS spectrographs are attributed to 
their advantage in providing both qualitative (identification and structure elucidation of 
chemical compounds) and quantitative analysis. Laboratories around the world are 
employing the use of MS instruments specifically because it complements well with the 
latest UPLC-system. Its sensitivity for detecting low concentrations takes advantage of the 
narrow peak width generated by the UPLC.  
Principle: after the sample is eluted from the column, it reaches the ionizer where it is 
nebulized; ions are then separated and detected according to their mass-to-charge ratio 
Fig. 3.2.7.1 UV detector diagram 
31 
 
(m/Z). A mass spectrometer consists of three main parts: (a) an ionizer; (b) a mass selector; 
and (c) a detector. 
In LC-MS, the column effluent is directed into the ionizer where it is nebulized under 
atmospheric pressure (Atmospheric Pressure Ionization). The ionization mechanism is 
achieved by either electrospray ionization (ESI) or atmospheric pressure chemical ionization 
(APCI). The ESI is considered a liquid-phase ionization technique; the ions in the solution are 
disperse by electrospray into aerosol, evaporated into gas-phase and subsequently 
analyzed; whereas the APCI is considered a gas-phase ionization technique based on the 
gas-phase ion-molecule reaction between the analyte molecules and the solvent-based 
reagent gas; these reactions are initiated by electrons from the corona discharge needle28.  
After nebulization of the sample, the ions are directed into the mass selector which 
separates the ions by manipulating their trajectories under electric and/or magnetic field 
according to their m/Z ratio29.  The analyzer operates under vacuum so that the ionized 
particles run freely in the chamber without hitting air molecules. The separated ions are 
detected by the detector and the signals are processed into mass spectra. 
 
Figure 3.5 Mass spectroscopy diagram30 
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3.2.8  QUANTIFICATION AND QUALITY OF DATA ANALYSIS  
3.2.8.1  METHOD DEVELOPMENT 
When working with testing equipment is it  important to ensure tha t when 
used as measurement equipment they  will measure correctly.  Performing 
a successful chromatographic method and generating quality data 
requires selection of a suitable method for the analysis and also an 
experienced staff.  Hence, before beginning with the analysis the 
performance of the instrument system should always be checked. 
Measuring instruments are calibrated with the help of various e quipment 
or in the case of HPLC by compa ring its responses with known standards.  
When evaluating chromatograms and instruments operation there are 
several important questions that need to be addressed: Do the peaks look 
normal (Gaussian)?; Is  the response obtained comparable to the response 
from previous calibrations?; Are non-target peaks present in calibration 
analyses?; Are contaminants present in the blanks?;  Is  the injector 
leaking?; Does the HPLC guard column need replacement? 31.  
 There are several methods used to calibrate LC -instruments prior to 
analysis.  
3.2.8.1.1  Internal standard calibration  
An internal standard in analytical chemistry is a chemical substance that 
is added in a constant amount to samples,  the blank and calibration 
standards in a chemical analysis 32.  The internal standard calibration is 
used to compare the instrument response between the reference standard 
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and the targeted compound.  The internal standard should show similar 
but not completely identical  behavior to the targ et compound; it  should 
be recovered to a simila r extent as the target compound and  be separated 
from all other substances in the sample.  The calibration is done by 
plotting the analyte/internal standard peak are or peak height ratio 2 2 .  
This ratio is  called the relative response factor (RRF) and is  used to 
obtain the analyte concentra tion from the calibration curve:  
RFF = (Ac x Cis)/(Ais x Cc) 
Ac – the peak area of the target analyte   
Ais – the peak area of the internal standard  
Cc – the concentration of the target analyte  
Cis - the concentration of the internal standard  
 The internal standard is a certified reference substance of the compound 
to be determined which is added at known concentration to standard 
solutions and to sample solutions prior to the analysis.  Th is method has 
shown to compensate for the analytical  errors due to sample losses and 
variable injection volumes  compared to the external  standard method33. 
3.2.8.1.2   External standard calibration  
The external standard is similar to the internal standard in that the 
sample solutions are compared with reference solution, but the key 
difference is that the external standard is not added to the sample 
solution but instead run separately under identical conditions.  
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3.2.8.1.3   Standard addition  
This method is used to determine the concentration of an analyte which 
is part of a complex matrix (e.g.  biological f luids) and contain substances 
that may interfere with the  detectors’ response. In this case,  plotting a 
calibration curve based on the analytes concentration would be incorrect 
due to the interferences of substances from the matrix.  Instead,  a  sample 
solution is “spiked” with a known analyte concentration and the change 
between the sample solution and the “spiked” sample is  monitored in the 
instruments response. This change is assumed to be only due to change  in 
analyte concentration.  
3.2.8.1.4  Normalization 
The normalization method is the most straightforward and easiest 
technique used in accessing quantitative analysis.  It  is applied in a 
limited number of analyses where the detectors’ response is the same for 
all the analytes present in the sample.  The resu lts are obtained by 




   
 x 100 
3.2.8.2  METHOD VALIDATION 
 Validation is a compulsory task for every analytical procedure in 
pharmaceutical analysis.  The requirements for validating a method are  
recommended by the International Conference on Harmonization of Technical 
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Requirements of Pharmaceuticals for Human Use (ICH), based on the document  
Validation of Analytical Procedure: Text and Methodology. Validation is a method 
used to demonstrate that an analytical procedure is suitable for its 
intended use.  It  comprises of a series of characteristics:  
3.2.8.2.1 Accuracy 
Accuracy of an analytical method describes the closeness between the 
results obtain from the procedure to that of the true  value (true 
concentration) of the analyte.  Accuracy should be reported in either of 
two ways:  
 The percentage of recovery by the assay of the known added 
amount of the analyte in the sample;  
 The difference between the mean and the accepted true value 22. 
For a method to be considered accurate,  the limit deviation of the mean and 
the true value is 85-115%, except for the LLOQ (lo w limit of quantification)  
which is 80-120%4. 
3.2.8.2.2 Precision 
Precision of an analytical method is usually expressed as the variance , or 
as the standard deviation  between a series of measurements obtained 
from a multiple sampling of the same homogenous sample under the 
prescribed conditions.  It  is  considered at three levels:  
 Repeatability  is  expressed as the precision under the same 
operating conditions over a short interval of time;  
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 Intermediate precision  expresses within laboratories variations: 
different days different analysts,  different equipment,  etc. ;  
 Reproducibility  expresses the precision between laboratories 34; 
The limit for the coefficient variation or the relative standard deviation 
is 85-115%, except for the LLOQ in which case it is 80-120%. 
3.2.8.2.3 Specificity 
Specificity or selectivity is the ability of an analytical method to assess 
the analyte concentration regardless of the presence of possible 
interfering substances (impurities,  endogenous matrix,  degradants).   
3.2.8.2.4 Detection limit 
The limit of  an analytical procedure is the lowest amount of the analyte 
that can be detected but not necessarily quantified as an exact value 3 4 .  
3.2.8.2.5 Quantification limit 
Limit of quantification is t he lowest limit for a given analyte that can be 
quantitatively determined by an analytical procedure. T he response 
(peak area) of the lowest standard should be 5 times higher than the 
response of a blank sample and should be reproducible with a precision 
of 20% and accuracy of 80-120%4 .   
3.2.8.2.6 Linearity 
The linearity (calibration or standard curve) shows the relationship of 
the instruments’ response and the known concentration of the analyte 4 .  
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According to the ICH, to establish the l inearity a minimum of five 




The range of an analytical procedure is the interval between the upper and 
lower concentration of analyte in the sample (including these  
concentrations) for which it has been d emonstrated that the analytical 
procedure has a suitable level of precision, accuracy and linear ity3 4 .  
3.2.8.2.8 Robustness 
The robustness of an analytical procedure is  a measure of its capacity to 
remain unaffected by small,  but deliberate variations i n method 
parameters and provides an indication of its reliability during normal 
usage.  Examples of typical variations in liquid chromatography are:  
variations of pH in the mobile phase; variations in composition of the 
mobile phase; variations in temperature and flow rate.  
 
Figure 3.6  Example of a calibration curve with five sample concentrations 
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3.3  ULTRA-FAST LIQUID CHROMATOGRAPHY 
 
3.3.1 The Evolution of smaller particles and the advantages of UFLC 
Ultra-fast  performance liquid chromatograph y is the newest 
separation technique in liquid chromatography. Although the HPLC 
was a proven technique that was routinely used in laboratories around 
the world,  the need for improving separation efficiency has led to the 
development of a more sophisticate d and advantageous instrument 
such as the UFLC. The principle on which the improvement of the 
separation efficiency lies is the decrease  in size of the packing 
material  in the column.  The decrease of particle size is explained by 
the van Deemter equation which describes the relationship of the 
decrease of  particle size with the linear velocity (flow rate) of the 
mobile phase moving through the column and the plate height (HETP 
or column efficiency) 35. 
 
 
Figure 3.7  Van Deemter curve that explains 
the effect of decreasing particle size in 
linear velocity and column efficiency 
39 
 
The increased flow rate does not affect the resolution and the sensitivity 
of the method, in fact it  improves it .  This is  explained from the 









     
 , 
which shows that the resolution is proportional to the square root of 




 ),  i f  dp is decreased by a facto r of three,  for example,  from 5 
µm (HPLC scale) to 1.7 (UFLC scale),  then N is increased by three and R s  
is increased by the square root of three or 1.7.  Another aspect that 
explains the increase in resolution is that N is also inversely proportional 
to the peak width (N = 1/w 2),  as the particle size is  decreased, the plate 
number increases and the peak width (w 2) decreases; meaning that  the 
narrower the peaks are,  the easier they are to be separated from one 
another.  In addition, the peak height is inver sely proportional to peak 
width; the narrower the peaks,  the taller  the peaks and thus the higher 
the sensitivity 3 5 .  
The use of smaller particles required for util ization  of higher pressure in 
order to push the mobile phase through the packed material in the 
column. UFLC a llows the use of pressure  up to 1000 bar which is one 
order of magnitude greater than pressure generated by the HPLC 36.  The 
drawback of the small particles was in the ability of the other 
compartments of the instruments to withstand the high back -pressures.  
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As a result  pumping system and sample injector had to be customized.  In 
a work done by MacNair 3 6 ,  they invented a static-split injector which 
could inject samples in much higher speed, were able to work under the 
highest pressure ever generated in liquid chromatography.  In addition, 
the high pressure accounted for increased heat in the column which 
would cause decomposition of the mobile phase and/or the sample 
molecules.  The problem was solved in the work of Wu37 were heat 
dissipation was achieved by using capillary columns.   
The evolution of smaller particles allowed for a better resolution,  an 
increase in sensitivity and faster analysis 38.   
The first ultra-fast l iquid chromatography apparatus was A CQUITY UPLC®  
designed by Waters.  The system adjustments involved a binary pump 
system that could withstands pressures  up to 1000 bar,  an autosampler 
and a sample injector that could perform fast  injection cycles,  low 











4 EXPERIMENTAL PART 
 
Apparatus 
Nexera Ultra-Fast Liquid Chromatography system with gradient elution 
capability and spectrophotometric UV detector ,  Shimadzu, Japan.  
Analytical column: KINETEX® ,  Column Protection KrudKatcher™ Ultra ,  
fittings Sur-Lok™ and Traditional;  column length 150 mm; internal 
diameter 2.1 mm, particle size 1.7 µm C18,  100Aº 
 
Conditions 
Mobile phase:  mixture:  eluent A (buffer) :  eluent B (50 : 50); the mobile 
phase was sonicated for a few minutes  
Flow rate: 0.15 ml/min  
Detection UV/Vis:  250 nm 
Injection volume: 3µL 
Acquisition time: 35 minutes  
Column oven temperature: 40ºC 
Diluent: eluent B  
 
Data comparison between HPLC and UFLC  and method conversion 
The method transfer from conventional HPLC to UFLC apparatus was 










Detector UV detector  UV detector  
Analytical column 
Merck LiChrocart 
Purospher star RP-18e  
KINETEX® ,  Column 
Protection 
KrudKatcher™ Ultra,  
fittings Sur-Lok™ and 
Traditional  
Column length 250 mm  150 mm  
Internal diameter  4 mm 2.1 mm 
Particle size 5 µm  1.7µm  
Mobile phase Mixture: Eluent   A(buffer) :  Eluent B (50:50)  
Flow rate 1.0 ml/min 0.15 ml/min 
Wavelength  250 nm 250 nm 




Acquisition time 60 min 35 min 
Diluent  Mixture of buffer : eluent B (50:50)  
 
Preparation of buffer (eluent A)  
1.54 mg of Ammonium acetate was weighted into a beaker containing 500 
ml of water.  The pH of the solution was adjusted to 9.0 ± 0.5 using 
Triethyl amine solution. The eluent was fi ltered through a 0.45µm 
membrane and sonicated in an ultrasonic bath for 5 minutes.  
The eluent was prepared just b efore use in order to avoid instabilities of 
the solution and possible errors during the analysis.  
 
Preparation of eluent B  
To prepare a 500 ml of eluent B,  Acetonitri le (150 ml) and Methanol (350 




Preparation of standard solution s  
Standard solution (a):  8.91 mg of quetiapine fumarate working standard 
were weighted accurately into a 25 ml volumetric flask,  sonicated and 
made up to colume with diluent.  
c=0.3564 mg/ml  
Standard solution (b):  1 ml of the standard solution (a) were  diluted to 
250 ml.  
c=0.0014 mg/ml  
 
Preparation of the system suitability test solution (SST):  
Approximately 1 mg of each of the working sta ndard substances of 
dibenzo impurity,  triethoxy impurity and quetiapine fumarate were 
weighted into a 100 ml volumet ric flask,  initially dissolved with 50 ml of 
methanol and subsequently diluted to make 100 ml solution.  
 
4.1.1  System Suitability Test  
Three injections of system suitability test solution and three injections of 
quetiapine standard solution were run to compare r etention times, check 
the tailing factors and resolution between peak areas.   





Dibenzo  6777 9,441 0,701 4,826 
Quetiapine 14188471 22,034 0,845 3,076 






Evaluation:  according to the Ph.Eur.  and USP requirements,  the tailing 
factors of the peak areas  obtained are within the limit range which is 0.8 
–  1.5.  The resolution of the peak areas also complies with the 
pharmacopoeia requirement,  where R s  of the three peaks is greater than 
2.  
 
4.1.2  Linearity 
To test  the linearity (response ) of the detector five concentrations of the 
sample where prepared. The conventional value for the minimum limit of 
impurities in a sample is  0.05%; in cases where the obtained value is 
lower than 0.05% the presence of the impurities is  considered to be 
irrelevant.  The conventional value for maximum limit  of impurities in a 
sample is  plus 50% of the minimum limit  of impurities.  
According to the manufacturer  of Questax® the value for maximum limit  
of impurities is 0.2%.  The maximum value for limit of impurities chosen 
in this work was 0.3%.  
Range concentration of the sample was divided in five parts as follows:  
0.05% (the minimum limit); 0.075%; 0.15%; 0.225% and 0.3%  (the 
maximum limit).  
 
# 1 2 3 4 5 






Sample concentration o f 100% quetiapine (150 mg of quetiapine in 250 
ml) is  c=0.6 mg/ml.  
-  For 0.3% of quetiapine the concentration was calculated to be  
 c=0.0018 mg/ml.   
-  For 0.05% of quetiapine the concentration was calculated to be 
c=0.0003 mg/ml.  
 
Procedure of preparing the range of five different concentrations: 
0.5 ml were taken from the standard solution of quetiapine with 
concentration c=0.3 mg/ml and diluted with diluent to make 50 ml 
quetiapine solution (c=0.003 mg/ml).  Furthermore, 6 ml were taken from 
the above solution and diluted with diluent to make 10 ml solution of 
0.3% quetiapine (c=0.0018 mg/ml,  the maximum limit  of impurities);  
4.5 ml were taken from the standard solution and  diluted with diluent to 
make 10 ml solution of 0.225% quetiapine;  
3 ml were taken from the standard solution and diluted with diluent to 
make 10 ml solution of 0.15% quetiapine;  
1.5 ml were taken from the standard solution and diluted with diluent to 
make 10 ml solution of 0.075% quetiapine;  
1 ml was taken from the standard solution and diluted with diluent to 
make 10 ml solution of 0.05% quetiapine (c=0.0003 mg/ml.  the minimum 
limit  of impurities).   
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A batch with the vials containing f ive different concentrations were each 











y = 155282x - 2314.5 
















Figure 4.1  Calibration curve obtained from the range of five different concentrations of the 
sample; c1=0.05%, c=0.075%, c=0.15%, 0.225%, 0.3%; each sample was injected twice 

























Evaluation:  the regression curve was calculated by the method of least 
squares: y = 155282x -2314.5,  where y is the peak area and x is the 
concentration. The square of R is the  correlation coefficient between these 
two variables and for the two variables to be in correlation R 2  should be 
higher or equal to 0.99. The square of the correlation coefficient obtained 
from this batch R2  = 0.9999 shows that the two variables are highly 
correlated which indicated that the detector was  linear and ready to 
continue for further analysis.  
 
4.1.3  Quantification Limit (LOQ) 
The lowest limit of the  sample concentration that was able to be quantified 
by the instrument was calculated by the signal -to-noise ratio.  
The S/N ratio was measured from the chromatogram showing the peak area 
of the lowest concentration of the sample solution (c=0.05%).  
 
Figure 4.2  Chromatogram of the peak area of the lowest limit of quantification 
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Evaluation:  The calculation was done using the formula: S/N=2H/h; the 
peak height (H) and the noise height (h) were measured and retrieved from 
the chromatogram.  
S/N = 16.44 for c = 0.0003  mg/ml; so for S/N = 10 which is the conventional 
pharmacopeia value  for the lowest concentration that the instrument can 
quantify,  the l imit  of quantification (LOQ) was found to be  0.0002 mg/ml 
and this value refers to the concentration of 0.03%.  
 
4.1.4  Detection Limit (LOD) 
Similarly,  the S/N ratio was measured from the chromatogram showing the 
peak area for the lowest limit  of concentration; and for S/N = 3 which is the 
conventional pharmacopoeia value for the lowest concentration that the 
instrument can detect,  the l imit  of detection (LOD) was found to be  
0.00005 mg/ml.  The value corresponds to  approximately 0.01%.  
 
4.1.5  Selectivity  
A batch containing the sample solution, quetiapine standard solution, SST 
solution and two placebo solution was run for the analysis to test the 
selectivity of the method. Chromatograms of each injection where compared.  
Placebo solutions were prepared according to the  recommendations of the 
manufacturer: 50 mg of placebo were weighted into a 50 ml volumetric 






- Sample solution of quetiapine fumarate 
- Quetiapine base standard solution 
- SST solution 
- Placebo solution of 100 mg quetiapine tablet  
- Placebo solution of 25 mg quetiapine tablet 
 
 
Evaluation:  according to the chromatograms, auxiliary substances  
present in Questax® 100mg and Questax® 25 mg tablets do not interfere 
with the active substance and its impurities  and the analytical method 
was evaluated to be selective.  
 
4.1.6 Precision 
The relative standard deviation was calculated to measure the extent of the precision to 
which individual test results of multiple injections of a series of standard agree. 
In this work, precision was considered by testing the repeatability of the method. 






















The following procedure was done to prepare six samples: 
74 mg of crushed powder of 25 mg tablet were weighted into a 50 ml volumetric flask. 
Thereafter, 30 ml of diluent (mobile phase) were added to dissolve the powder. The 
mixture was sonicated for 15 minutes and then left to cool down at room temperature. 
After cooling, the mixture was filled up to the mark with diluent and filtrated through a 
0.45 µm membrane. 
The six samples where each injected twice. The average peak area of two injections was 
calculated. The response factor for dibenzo impurity is 1.38 and for triethoxy impurity 
is 0.85. Assay for known individual impurities was calculated using the formula: 
 
% = 
    
  
                                        








P1 6780.5 4913.405797 0.037306 
P2 6434.5 4662.681159 0.035402 
P3 6380 4623.188406 0.035102 
P4 6242 4523.188406 0.034343 
P5 6188 4484.057971 0.034046 
P6 6693 4850 0.036824 










P1 821 965.88 0.0073 
P2 859 1010.59 0.0077 
P3 831.5 978.23 0.0074 
P4 899 1057.68 0.0080 
P5 920.5 1082.94 0.0082 
P6 889 1045.88 
 
0.0078 
total 870 1023.53 0.0077 
 
 
Precision is usually expressed by the relative standard deviation: 
 
% RSD = 
                          
             
 x 100 
The calculations were done in excel: 
 
 RSD (%) 
Dibenzo impurity 3.26 
Triethoxy impurity 4.42 
 
 
Requirements for precision for related substances in preparation are: 
 
c % 
1,0 % ≤ Ci 5 
0,1 % ≤ Ci < 1,0 % 7 





4.1.7  Accuracy 
Sample preparation 
The procedure of preparing the samples for accuracy was the same as in 
samples preparation for precision, with the exception of adding known 
amount of impurities to the sample solution, which had to be calculated.  
Firstly,  the concentration of each impurity i n the SST solution was 
calculated according to the formula:  
 
c (mg/ml) = 
    
  
                                          
                          
  
 
Dibenzo impurity c = 0.0146; Triethoxy impurity c = 0.0084.  
Secondly,  the amount of each of the impurities to be added to the SST 
solution was calculated  as follows:  
-  the concentration of 100% quetiapine in SST solution was c = 0.6 
mg/ml.  The percentage of impurities present in the SST solution has to be 
within the range of the lowest LOQ and the highest limit  on the 
calibration curve. The chosen point to be taken as the true value for 
triethoxy impurity was  0.05%, for which the concentration was found to 
be 0.01512 mg/50 ml.  Because 0.01512 mg was a very small amount  to 
weigh, instead,  the ml needed to be added in the sample were calculated 
as follows:  if  1ml of SST solution contains 0.0084 mg of triethoxy, then 
0.01512 mg accounts for  1.8 ml of SST.   
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The amount of dibenzo impurity in 1.8 ml of SST solution,  with a 
concentration of 0.0146 mg/ml,  was found to be 0.02628 mg.  If a  100% 
solution of quetiapine standard contains 30 mg of quetiapine (0.6 mg/ml 
x 50 ml),  percentage of dibenzo impurity in 50 ml of sample solution was 
calculated as 0.08732%.  
True values that were added to the sample : Triethoxy 0.050531%; 
Dibenzo 0.08732%. 
The tables below show the comparison between found value and the true 
value and also,  the recovery of the assay of the known added amount of 
impurities in the sample was calculated with the formula:  
 
% = 
           
          

























A1 21,161 15333.70 0.1163 0.0373 0.0810 0.0873 92.80 
A2 20819.5 15086.60 0.1144 0.0354 0.0792 0.0873 90.66 
A3 21436 15533.33 0.1178 0.0351 0.0825 0.0873 94.54 
A4 21470 15557.97 0.1180 0.0343 0.0827 0.0873 94.76 
A5 21564 15626.10 0.1185 0.0340 0.0832 0.0873 95.35 
A6 21228.5 15382.97 0.1167 0.0368 0.0814 0.0873 93.24 
average 21,280 15,420 0.1170 0.0355 0.0822 0.0873 93.56 
 
 
Figure 4.4 Table showing the average of 2 injections of six samples prepared for accuracy and the 



























A1 6915 8135.30 0.0617 0.0073 0.0540 0.0505 106.81 
A2 6782 7978.82 0.0605 0.0077 0.0529 0.0505 104.46 
A3 6941.5 8166.47 0.0620 0.0074 0.0542 0.0505 107.28 
A4 6856 8065.88 0.0612 0.0080 0.0534 0.0505 105.77 
A5 6852.5 8061.76 0.0612 0.0082 0.0534 0.0505 105.71 
A6 6833 8038.82 0.0610 0.0079 0.0532 0.0505 105.36 
total 6879.6 8093.65 0.0614 0.0077 0.0537 0.0505 105.90 
 
 
Evauation:  the percentage of recovery complies with the requirements 
for accuracy for related substances in preparation. For concentration s:  
 
c % 
1,0 % ≤ Ci 
90 – 110 % 
 
0,1 % ≤ Ci < 
1,0 % 
85 – 115 % 
 
LOQ % ≤ Ci < 
0,1 % 
 








Figure 4.5 Table showing the average of 2 injections of six samples prepared for accuracy and the 
resulting recovery % for the triethoxy impurity. 
Figure 4.6 The Eu.Phar and USP requirements of accuracy for related 
substances in the preparation 
55 
 
5 RESULTS AND CONCLUSION 
The method was developed for determination of related substances of Quetiapine 
Fumarate (Questax®) by Ultra-fast liquid chromatography system with gradient elution 
capability and spectrophotometric UV detector, particle size of 1.7 µm with flow rate of 
0.15 ml/min. The suitability of the method was validated by the parameters of linearity, 
LOQ and LOD, precision and accuracy and the results of the experiment are shown 
below: 
System suitability test: an SST solution containing both the active substance and the 
impurity contents was injected with each batch during the validation procedure. The 
method was shown to be suitable as the tailing factor of the peaks was kept within the 
limit range of 0.8 – 1.5; also, the resolution of each of the peak areas was in all cases 
greater than 2, which complies with the Ph.Eur.  and USP requirements.  
Linearity:  the validity of  the method was further ensured as the 
correlation coefficient (R 2) obtained from the procedure was 0.999, 
which shows that the two variables,  peak areas and the range of five 
different concentrations of the sample highly correlate with each other.  
For the method to be linear,  the correlation coefficient should be higher 
or equal to 0.99.  
Quantification Limit:  the lowest quantification limit was measured using 
the S/N ratio of the peak area with the lowest concentration of the 
sample solution (0.05%. The co ncentration was found to be 0.0002 
mg/ml which refers to 0.03% of the sample solution.  
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Detection Limit:  the lowest detection limit was measured similarly as for 
LOQ and the lowest concentration to be detected was found to be 0.00 005 
mg/ml,  which is approximately 0.01% of the sample solution.  
Selectivity:  the specificity of the analytical  method was determined by 
injecting two placebo solutions simultaneously with the SST and standard 
solutions,  and according to the chromatograms of the peak areas,  the 
excipients of the preparation do not interfere with neither with the 
active substance nor with its impurities.  
Precision:  the extent of the precision of the method was measured by the 
relative standard deviation (%RSD) of  multiple injections of a series of 
standards. The RSD of two impurities with contents lower than 0.1%, were 3.27% for 
dibenzo and 4.42% for triethoxy. According to the requirements for precision for 
related substances in preparation, for substances with concentration lower than 0.1% 
the RSD value should be more than 10%. 
Accuracy:  the accuracy of the method was conducted by measuring the percentage of 
recovery of the known added amount of the impurity to the sample solution. The limit 
of deviation between the mean value and the true value obtained from the procedure 
was RSD = 93.56% for dibenzo impurity (c (%) = 0.0355%) and RSD = 105.90% for 
triethoxy impurity (c (%) = 0.0077). According to the requirements for accuracy for 
related substances in preparation, for substances with c <0.1% the RSD value should be 
in the range limit of 80 – 120%. 
CONCLUSION:  The newly developed method of UFLC was successfully validated as 
shown in the results in the validation procedure. The results obtained in this work 
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show that the method transfer from conventional HPLC to UFLC method was successful 
in that it shortened the analysis time for up to 30 minutes and the resolution of the 
method was increased by 1.7 which accounts for the improvement of the separation 
efficiency. Overall, the applicability of UFLC system compared to that of the 
conventional HPLC system, despite the high cost of the instrument, is highly more 
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